Thalassemia Patients and Friends

Discussion Forums => Working Towards a Cure => Topic started by: CrazyPharm on December 22, 2014, 10:51:44 AM

Title: Luspatercept vs. Sotatercept
Post by: CrazyPharm on December 22, 2014, 10:51:44 AM

Can anyone highlight the differences between Sotatercept and Luspatercept. Apparently Acceleron and Celgene will most likely be moving forward with only one of these drugs? does anyone have some info. on this?

Also, their phase II trial in Thalassemia received funding from Novartis. Confused but how does Novartis tie into this? I know Dr. Piga has worked with them but aside from that...bluntly speaking: what's in it for them? :huh

Title: Re: Luspatercept vs. Sotatercept
Post by: Andy Battaglia on December 22, 2014, 03:37:10 PM

Contrary to popular perception, it is far more likely for a company like Novartis to buy a company for an already developing drug, than to develop one themselves. I would say Novartis has a potential future financial interest.

Title: Re: Luspatercept vs. Sotatercept
Post by: CrazyPharm on December 22, 2014, 04:11:07 PM

Thanks Andy, my thoughts exactly! Novartis seems to jump on Thalassemia drugs. On a different note: any idea when the Brand patent on Exjade expires?

Title: Re: Luspatercept vs. Sotatercept
Post by: ama on December 22, 2014, 08:13:14 PM

Exjade Patent is supposed to expire on April 5, 2019.